honoluluadvertiser.com

Sponsored by:

Comment, blog & share photos

Log in | Become a member
The Honolulu Advertiser

Posted at 4:07 a.m., Monday, October 15, 2007

Hawaii nutrition firm announces product developments

News Release

KAILUA KONA, Hawaii-- Cyanotech Corporation (Nasdaq:CYAN), a world leader in producing high-value nutrition and health products from microalgae, announced three important product developments.

The company has added two new product formulations to its Nutrex Hawaii (www.nutrex-hawaii.com) product line. The synergistic formulas address condition-specific needs of its customers. Named MD Formulas Hawaii™, the products embrace the informed consumer philosophy of Proactive Health Maintenance championed by Drs. Bob Corish and Leonard Smith, who collaborated with Cyanotech in the formulations. Contact info@nutrex-hawaii.com for more information.

CardioAstin™ delivers the most powerful natural antioxidant known, BioAstin, Cyanotech's proprietary Natural Astaxanthin, to support a healthy cardiovascular system. The BioAstin acts synergistically with other key ingredients, including CoQ10, Lutein, Acetyl L-Carnitine, DHA and Omega-3 EFAs, to facilitate their bioavailability and enhance their effects.

JointAstin™ is a powerful formula combining BioAstin Natural Astaxanthin with 100% vegetable source Glucosamine to strengthen, support and nourish joints, tendons and synovial fluids. It is the first non-animal source, completely vegetarian joint formula on the market.

The company also has received GMP (Good Manufacturing Practices) certification from the Natural Products Association, demonstrating the company's continuing role as the leader in quality among microalgae producers. Cyanotech was the first microalgae company in the world to be ISO certified, and is one of only two Spirulina manufacturers that have attained the US FDA's GRAS status (Generally Recognized as Safe).

"Cyanotech has been operating under GMP guidelines for many years, but this official GMP certification confirms that we follow strict quality guidelines," said Cyanotech's founder and CEO, Dr. Gerald R. Cysewski. "In this age of uncertainty in sourcing products, it is very important for our customers to know that they can obtain outstanding quality Natural Astaxanthin and Spirulina from Cyanotech."

Cyanotech Corporation, a world leader in microalgae technology, produces BioAstin® Natural Astaxanthin and Hawaiian Spirulina Pacifica®—all natural, functional nutrients that enhance human health and nutrition. Cyanotech's spirulina, FDA reviewed and accepted as Generally Recognized as Safe (GRAS) for use as a food ingredient, augments energy and immune response. BioAstin's benefits derive from its superior antioxidant activity and from its ability to support and maintain natural inflammatory response, enhancing skin, muscle and joint health. NatuRose® Natural Astaxanthin is a natural pigment source that also promotes animal health and nutrition, primarily in aquaculture. Phycobiliproteins are fluorescent pigments used in medical diagnostic testing and research. Cyanotech produces these products from microalgae grown at its 90-acre facility in Hawaii using patented and proprietary technology and distributes them to nutritional supplement, nutraceutical, cosmeceutical, and animal feed makers and marketers in more than 40 countries worldwide. Cyanotech was the first microalgae company in the world to obtain ISO 9001:2000. Visit www.cyanotech.com for more information.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, forecasts of sales in future periods, changes in sales levels to our largest customers, weather patterns, production problems caused by contamination, risks associated with the acceptance of new products, competition, foreign exchange fluctuations, government regulation, and other factors more fully detailed in the Company's recent Form 10-Q and annual form 10-K filings with the Securities and Exchange Commission.